Patents by Inventor Richard Harrop

Richard Harrop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11427645
    Abstract: The present invention relates to immunotherapeutic approaches to treating haematological cancers. In particular the invention relates to a method for treating a haematological cancer by targeting the 5T4 antigen. As such, the invention provides a method for treating haematological cancers comprising administering to a subject a 5T4-targeting agent. The invention also provides a 5T4-specific chimeric antigen receptor (CAR) and uses thereof in treating cancers.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: August 30, 2022
    Assignee: OXFORD BIOMEDICA (UK) LIMITED
    Inventor: Richard Harrop
  • Publication number: 20200010560
    Abstract: The present invention relates to immunotherapeutic approaches to treating haematological cancers. In particular the invention relates to a method for treating a haematological cancer by targeting the 5T4 antigen. As such, the invention provides a method for treating haematological cancers comprising administering to a subject a 5T4-targeting agent. The invention also provides a 5T4-specific chimeric antigen receptor (CAR) and uses thereof in treating cancers.
    Type: Application
    Filed: March 14, 2018
    Publication date: January 9, 2020
    Inventor: Richard Harrop
  • Publication number: 20160231315
    Abstract: A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 11, 2016
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventor: Richard Harrop
  • Publication number: 20160195554
    Abstract: A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of haematocrit and haemoglobin in a sample from the cancer patient, and (b) comparing the level of haematocrit in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of haematocrit and higher level of haemoglobin in the sample correlates with increased benefit to the patient.
    Type: Application
    Filed: August 5, 2015
    Publication date: July 7, 2016
    Inventors: Richard Harrop, Peter Treasure
  • Patent number: 8642274
    Abstract: The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: February 4, 2014
    Assignee: Oxford Biomedica, Inc.
    Inventors: Richard Harrop, William Shingler, Stuart Naylor, Michael McDonald
  • Publication number: 20130217116
    Abstract: There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.
    Type: Application
    Filed: January 31, 2011
    Publication date: August 22, 2013
    Inventors: Miles Carroll, Richard Harrop, Susan Kingsman
  • Publication number: 20120213822
    Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 23, 2012
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
  • Publication number: 20120107862
    Abstract: A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of haematocrit and haemoglobin in a sample from the cancer patient, and (b) comparing the level of haematocrit in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of haematocrit and higher level of haemoglobin in the sample correlates with increased benefit to the patient.
    Type: Application
    Filed: November 1, 2011
    Publication date: May 3, 2012
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, Peter Treasure
  • Patent number: 8147838
    Abstract: The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their used in diagnosis and therapy of cancer.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: April 3, 2012
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Richard Harrop, William Shingler, Susan Mary Kingsman
  • Patent number: 8133681
    Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: March 13, 2012
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
  • Publication number: 20120039943
    Abstract: A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient.
    Type: Application
    Filed: January 8, 2010
    Publication date: February 16, 2012
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventor: Richard Harrop
  • Patent number: 7910109
    Abstract: There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: March 22, 2011
    Assignee: Oxford Biomedica (UK) Ltd.
    Inventors: Miles Carroll, Susan Kingsman, Richard Harrop
  • Publication number: 20100158884
    Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.
    Type: Application
    Filed: February 3, 2010
    Publication date: June 24, 2010
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, Miles William Carroll, Susan Mary Kingsman
  • Publication number: 20100124534
    Abstract: The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response
    Type: Application
    Filed: July 15, 2009
    Publication date: May 20, 2010
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, William Shingler, Stuart Naylor, Michael McDonald
  • Publication number: 20090280138
    Abstract: The present invention relates to peptide epitopes of 5T4 antigen and their use in immunotherapy. In particular, the present invention relates to any one of the peptide epitopes as described herein as well as their use in diagnosis and therapy of cancer.
    Type: Application
    Filed: May 12, 2006
    Publication date: November 12, 2009
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, William Shingler, Susan Kingsman
  • Publication number: 20090191230
    Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.
    Type: Application
    Filed: July 10, 2006
    Publication date: July 30, 2009
    Applicant: Oxford Biomedica (UK) Limited
    Inventors: Richard Harrop, Miles W. Carroll, Susan M. Kingsman
  • Patent number: 7541044
    Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumor immune response in a human patient.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: June 2, 2009
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Richard Harrop, Miles Carroll, Susan Kingsman
  • Publication number: 20090047307
    Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.
    Type: Application
    Filed: March 20, 2008
    Publication date: February 19, 2009
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
  • Publication number: 20070086992
    Abstract: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.
    Type: Application
    Filed: September 29, 2006
    Publication date: April 19, 2007
    Applicant: Oxford Biomedica (UK) Ltd.
    Inventors: Richard Harrop, Miles Carroll, Susan Kingsman
  • Publication number: 20050118597
    Abstract: There is provided an MHC class II peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the minimal epitope from the amino acid sequence shown as SEQ ID No. 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID No. 3; (iii) a minimal epitope from the region 281-420 of 5T4. There is also provided a vaccine comprising such a peptide (or precursor thereof) and its use to treat and/or prevent a disease, in particular a cancerous disease.
    Type: Application
    Filed: February 13, 2003
    Publication date: June 2, 2005
    Inventors: Miles Carroll, Richard Harrop, Susan Kingsman